Amylyx Pharmaceuticals Inc (AMLX) — Institutional Holders Breakdown (Q2 2026)

AMLX ranks #2899 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

AMLX is a top-conviction position for Saturn V Capital Management LP — at 11.9% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in AMLX belongs to FMR LLC, but the position matters far more to Saturn V Capital Management LP, who has 11.9% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Fidelity has added to its AMLX position for two straight quarters, increasing it by $100.9M to reach $300.4M today.

Logos Global Management LP has trimmed its AMLX position for two straight quarters, cutting it by $5.2M while still holding $6.3M.

AMLX is up 2% today, and institutions have been net buyers of $56.8M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

AMLX reported a net loss of $152.1M over the trailing twelve months.

• Not yet profitable — net loss of $152.1M over the trailing twelve months
• Revenue declined 100.0% year over year
• Net income improved year over year, from -$187.6M to -$152.1M
• Operating cash flow was negative, using $123.3M in cash
• Current ratio of 14.27x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.09x equity — within a conventional range